EUCTR2015-005241-31-DE进行中（未招募）1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - Ataxia Telangiectasia - Treatment with EryDex SysTem - ATTEST
EryDel S.p.A.0 个研究点目标入组 175 人开始时间: 2016年5月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient meets clinical criteria for diagnosis of AT. The neurological signs of AT (incoordination of the head and eyes in lateral gaze deflection, gait ataxia associated with an inappropriately narrow base) must be documented. Such signs of AT illustrate the body systems in
- •which changes shall be confirmed but the listed changes are examples
- •and other changes in those systems may be observed and documented to
- •confirm the diagnosis of AT.
- •2. Patient is in autonomous gait or is helped by periodic use of a support (i.e. local ICARS score for Item 1 – Walking Capacities between 0 and 4,
- •3. Patient will be investigated for the proven genetic diagnosis of AT (prior documentation or by central laboratory test report).
- •4. Patient is at least 6 years of age, of either sex
- •5. Body weight > 15 kg.
- •6. The patient and his/her parent/caregiver (if below the age of consent), or a legal representative, has provided written informed consent to participate. If consent is provided solely by the caregiver in accordance with local regulations, the patient must provide assent to participate in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 180
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 9
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Females that are
- •a. pregnant, or are breast-feeding (for EU countries only);
- •b. of childbearing potential, pregnant, or are breast-feeding (for US and Rest of World countries).
- •Females of childbearing potential using adequate birth control, as determined by their Health Care Provider, will be eligible.
- •2. A disability that may prevent the patient from completing all study requirements.
- •3. Current participation in another clinical study.
- •Medical History and Current Status
- •4. CD4+ lymphocytes count <400/mm3 (for patients 6 years of age) or
- •<150/mm3 (for patients > 6 years). In presence of oral infections, like
- •oral candidiasis, documented at the screening or recurrent as per
- •medical history documentation, the limit increases to <200/mm3 (for patients >6 years).
- •5. Loss/removal of 250 mL or more of blood within the past 4 weeks prior to screening.
- •6. Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years.
- •7. History of severe impairment of the immunological system.
- •8. Severe or unstable pulmonary disease.
- •9. Uncontrolled diabetes.
- •Patients with diabetes that has been stabilized (i.e. no hypoglycemic or hyperglycemic episodes in the past 3 months) will be eligible.
- •10. Any other severe, unstable, or serious disease or condition that in the Investigator’s opinion would put the patient at risk for imminent life-threatening morbidity, need for hospitalization, or mortality.
- •11. Any clinically significant abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis) at screening that remains abnormal on repeat testing. Eligibility of patients with abnormal laboratory test values will be determined by the Investigator in consultation with the Medical Monitor.
- •12. Confirmed hemoglobinopathies, e.g. hemoglobin C disease, sickle cell anemia, or thalassemia.
- •13. Moderate or severe renal and/or hepatic impairment.
- •Prior/Concomitant Medication
- •14. Any previous oral or parenteral steroid use within 4 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted.
- •15. Chronic condition or prior allergic reaction representing a contraindication to the use of dexamethasone or other steroid drugs.
- •16. Has participated in any other trial with an investigational drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the 30-day Screening Period.
- •17. Has participated in a previous trial with EDS.
- •18. Requires any concomitant medication prohibited by the protocol.
- •19. Has taken a drug or treatment known to cause major organ system toxicity during the past year.
- •20. Use of any drug that is a strong inducer/inhibitor of CYP3A4 within 4 weeks before baseline.
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - AMG 785 20062017Acceleration of fracture healingMedDRA version: 12.1Level: LLTClassification code 10043827Term: Tibia fractureEUCTR2008-008392-34-ITAmgen Inc.400
进行中（未招募）
1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT) - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT)Acceleration of fracture healingMedDRA version: 13.1 Level: PT Classification code 10043827 Term: Tibia fracture System Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2008-008392-34-GBAmgen Inc400
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo. - RADIANTEUCTR2005-001747-29-ESOSI Pharmaceuticals, Inc.945
进行中（未招募）
不适用
Study of AMG785 in hip fractureAcceleration of fracture healingMedDRA version: 14.1Level: PTClassification code 10016454Term: Femur fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2009-015939-33-BEAmgen Inc330
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine theEfficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Proximal Femur, Status Post Fixation with a Sliding Hip Screw or Intramedullary NailEUCTR2009-015939-33-SEAmgen Inc330